Yamanaka M, Suda S, Kabasawa Y, Kawamura T, Ogawa T, Sawada K, Ohhara H
Eisai Tsukuba Research Laboratories, Ibaraki, Japan.
Chem Pharm Bull (Tokyo). 1992 Jun;40(6):1486-93. doi: 10.1248/cpb.40.1486.
Structural modification of the cardiotonic agent, loprinone (E-1020, 1), suggested by data that it has a less positive chronotropic effect than milrinone (15), led us to find novel bradycardic agents that were structurally different from homoveratryl amine derivatives. Alkyl-oxy, -thio, and -amino derivatives at the 2-position of the pyridine ring of 1 produced bradycardic activity without a significant effect on blood pressure and myocardial contractility. Aryloxy analogues also decreased heart rate, and members with an electron-withdrawing group at the ortho position of the phenyl ring showed higher activity. Replacement of the imidazo[1,2-alpha]pyridine with pyridine resulted in diminished activity. The mechanism of bradycardic activity of these compounds seems to be direct action on the sinus node.
强心剂洛普力农(E-1020,1)的结构修饰是基于其变时性效应不如米力农(15)明显的数据而进行的,这引导我们去寻找结构不同于高藜芦胺衍生物的新型心动过缓药物。1的吡啶环2位上的烷氧基、烷硫基和氨基衍生物产生了心动过缓活性,而对血压和心肌收缩力没有显著影响。芳氧基类似物也降低了心率,并且在苯环邻位带有吸电子基团的成员表现出更高的活性。用吡啶取代咪唑并[1,2-α]吡啶导致活性降低。这些化合物的心动过缓活性机制似乎是对窦房结的直接作用。